Navamedic ASA provided revenue guidance for the first half of 2022. The company has decided to provide a trading update based on estimated organic revenue growth for the first half of 2022 in excess of 30%. The high revenue growth is a result of a strong June 2022 and is driven by significant demand for Mysimba as well as other key products in the portfolio.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.3 NOK | +1.78% |
|
+0.88% | -6.54% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.54% | 55.94M | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- NAVA Stock
- News Navamedic ASA
- Navamedic ASA Provides Revenue Guidance for the First Half of 2022